Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B-Reference-Cited by-同舟云学术

Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B

Published:2020-11 Issue:5 Volume:73 Page:1037-1045
ISSN:0168-8278
Container-title:Journal of Hepatology
language:en
Short-container-title:Journal of Hepatology

Author:

Papatheodoridis George V.^ORCID,Dalekos George N.^ORCID,Idilman Ramazan,Sypsa Vana,Van Boemmel Florian^ORCID,Buti Maria,Calleja Jose Luis,Goulis John,Manolakopoulos Spilios,Loglio Alessandro^ORCID,Papatheodoridi Margarita^ORCID,Gatselis Nikolaos,Veelken Rhea,Lopez-Gomez Marta,Hansen Bettina E.,Savvidou Savvoula^ORCID,Kourikou Anastasia,Vlachogiannakos John^ORCID,Galanis Kostas,Yurdaydin Cihan^ORCID,Esteban Rafael,Janssen Harry L.A.^ORCID,Berg Thomas,Lampertico Pietro^ORCID

Publisher

Elsevier BV

Subject

Hepatology

Reference33 articles.

1. Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review;Papatheodoridis;J Hepatol,2010

2. Risk of hepatocellular carcinoma in chronic hepatitis B: assessment and modification with current antiviral therapy;Papatheodoridis;J Hepatol,2015

3. Eight-year survival in chronic hepatitis B patients under long-term entecavir or tenofovir therapy is similar to the general population;Papatheodoridis;J Hepatol,2018

4. Hepatocellular carcinoma in chronic hepatitis B patients under antiviral therapy;Vlachogiannakos;World J Gastroenterol,2013

5. PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy;Papatheodoridis;J Hepatol,2016

Cited by 75 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Tenofovir Is Associated With a Better Prognosis Than Entecavir for Hepatitis B Virus–Related Hepatocellular Carcinoma;Clinical Gastroenterology and Hepatology;2024-07

2. Preclinical Antiviral and Safety Profiling of the HBV RNA Destabilizer AB-161;Viruses;2024-02-21

3. Risk of hepatocellular carcinoma after curative treatment when switching from tenofovir disoproxil fumarate or entecavir to tenofovir alafenamide: A real‐world multicenter cohort study;Hepatology Research;2024-02

4. Entecavir versus tenofovir for prevention of hepatitis B virus-associated hepatocellular carcinoma after curative resection: study protocol for a randomized, open-label trial;Trials;2024-01-05

5. Nucleos(t)ide analogs for hepatitis B virus infection differentially regulate the growth factor signaling in hepatocytes;Hepatology Communications;2024-01